128 related articles for article (PubMed ID: 29371974)
1. Novel proteasome inhibitor delanzomib sensitizes cervical cancer cells to doxorubicin-induced apoptosis via stabilizing tumor suppressor proteins in the p53 pathway.
Guo KY; Han L; Li X; Yang AV; Lu J; Guan S; Li H; Yu Y; Zhao Y; Yang J; Zhang H
Oncotarget; 2017 Dec; 8(69):114123-114135. PubMed ID: 29371974
[TBL] [Abstract][Full Text] [Related]
2. Delanzomib, a novel proteasome inhibitor, sensitizes breast cancer cells to doxorubicin-induced apoptosis.
Wang M; Liang L; Lu J; Yu Y; Zhao Y; Shi Z; Li H; Xu X; Yan Y; Niu Y; Liu Z; Shen L; Zhang H
Thorac Cancer; 2019 Apr; 10(4):918-929. PubMed ID: 30883017
[TBL] [Abstract][Full Text] [Related]
3. Proteasome inhibitor MG132 sensitizes HPV-positive human cervical cancer cells to rhTRAIL-induced apoptosis.
Hougardy BM; Maduro JH; van der Zee AG; de Groot DJ; van den Heuvel FA; de Vries EG; de Jong S
Int J Cancer; 2006 Apr; 118(8):1892-900. PubMed ID: 16287099
[TBL] [Abstract][Full Text] [Related]
4. Second-generation proteasome inhibitor carfilzomib sensitizes neuroblastoma cells to doxorubicin-induced apoptosis.
Guan S; Zhao Y; Lu J; Yu Y; Sun W; Mao X; Chen Z; Xu X; Pan J; Sun S; Yang J
Oncotarget; 2016 Nov; 7(46):75914-75925. PubMed ID: 27713150
[TBL] [Abstract][Full Text] [Related]
5. Proteasome inhibition mediates p53 reactivation and anti-cancer activity of 6-gingerol in cervical cancer cells.
Rastogi N; Duggal S; Singh SK; Porwal K; Srivastava VK; Maurya R; Bhatt ML; Mishra DP
Oncotarget; 2015 Dec; 6(41):43310-25. PubMed ID: 26621832
[TBL] [Abstract][Full Text] [Related]
6. Novel, orally active, proteasome inhibitor, delanzomib (CEP-18770), ameliorates disease symptoms and glomerulonephritis in two preclinical mouse models of SLE.
Seavey MM; Lu LD; Stump KL; Wallace NH; Ruggeri BA
Int Immunopharmacol; 2012 Jan; 12(1):257-70. PubMed ID: 22178195
[TBL] [Abstract][Full Text] [Related]
7. Probing the specificity and activity profiles of the proteasome inhibitors bortezomib and delanzomib.
Berkers CR; Leestemaker Y; Schuurman KG; Ruggeri B; Jones-Bolin S; Williams M; Ovaa H
Mol Pharm; 2012 May; 9(5):1126-35. PubMed ID: 22432738
[TBL] [Abstract][Full Text] [Related]
8. Next-generation proteasome inhibitor oprozomib enhances sensitivity to doxorubicin in triple-negative breast cancer cells.
Shi Y; Bieerkehazhi S; Ma H
Int J Clin Exp Pathol; 2018; 11(5):2347-2355. PubMed ID: 31938346
[TBL] [Abstract][Full Text] [Related]
9. Novel proteasome inhibitor ixazomib sensitizes neuroblastoma cells to doxorubicin treatment.
Li H; Chen Z; Hu T; Wang L; Yu Y; Zhao Y; Sun W; Guan S; Pang JC; Woodfield SE; Liu Q; Yang J
Sci Rep; 2016 Sep; 6():34397. PubMed ID: 27687684
[TBL] [Abstract][Full Text] [Related]
10. Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53.
Herrmann JL; Briones F; Brisbay S; Logothetis CJ; McDonnell TJ
Oncogene; 1998 Dec; 17(22):2889-99. PubMed ID: 9879995
[TBL] [Abstract][Full Text] [Related]
11. Both Rb and E7 are regulated by the ubiquitin proteasome pathway in HPV-containing cervical tumor cells.
Wang J; Sampath A; Raychaudhuri P; Bagchi S
Oncogene; 2001 Aug; 20(34):4740-9. PubMed ID: 11498796
[TBL] [Abstract][Full Text] [Related]
12. Proteasome inhibitor MG132 induces thyroid cancer cell apoptosis by modulating the activity of transcription factor FOXO3a.
Qiang W; Sui F; Ma J; Li X; Ren X; Shao Y; Liu J; Guan H; Shi B; Hou P
Endocrine; 2017 Apr; 56(1):98-108. PubMed ID: 28220348
[TBL] [Abstract][Full Text] [Related]
13. Delanzomib, a Novel Proteasome Inhibitor, Combined With Adalimumab Drastically Ameliorates Collagen-Induced Arthritis in Rats by Improving and Prolonging the Anti-TNF-α Effect of Adalimumab.
Wang L; Liu L; Hong X; Liu D; Cheng Z
Front Pharmacol; 2021; 12():782385. PubMed ID: 34880764
[TBL] [Abstract][Full Text] [Related]
14. Withaferin A induces p53-dependent apoptosis by repression of HPV oncogenes and upregulation of tumor suppressor proteins in human cervical cancer cells.
Munagala R; Kausar H; Munjal C; Gupta RC
Carcinogenesis; 2011 Nov; 32(11):1697-705. PubMed ID: 21859835
[TBL] [Abstract][Full Text] [Related]
15. Enhanced anti-cancer effect of a phosphatidylinositol-3 kinase inhibitor and doxorubicin on human breast epithelial cell lines with different p53 and oestrogen receptor status.
Wang YA; Johnson SK; Brown BL; McCarragher LM; Al-Sakkaf K; Royds JA; Dobson PR
Int J Cancer; 2008 Oct; 123(7):1536-44. PubMed ID: 18634052
[TBL] [Abstract][Full Text] [Related]
16. Regulation of expression of BIK proapoptotic protein in human breast cancer cells: p53-dependent induction of BIK mRNA by fulvestrant and proteasomal degradation of BIK protein.
Hur J; Bell DW; Dean KL; Coser KR; Hilario PC; Okimoto RA; Tobey EM; Smith SL; Isselbacher KJ; Shioda T
Cancer Res; 2006 Oct; 66(20):10153-61. PubMed ID: 17047080
[TBL] [Abstract][Full Text] [Related]
17. Proteasome inhibitors induce a p38 mitogen-activated protein kinase (MAPK)-dependent anti-apoptotic program involving MAPK phosphatase-1 and Akt in models of breast cancer.
Shi YY; Small GW; Orlowski RZ
Breast Cancer Res Treat; 2006 Nov; 100(1):33-47. PubMed ID: 16807678
[TBL] [Abstract][Full Text] [Related]
18. Tanshinone IIA inhibits viral oncogene expression leading to apoptosis and inhibition of cervical cancer.
Munagala R; Aqil F; Jeyabalan J; Gupta RC
Cancer Lett; 2015 Jan; 356(2 Pt B):536-46. PubMed ID: 25304375
[TBL] [Abstract][Full Text] [Related]
19. p53-Independent up-regulation of a TRAIL receptor DR5 by proteasome inhibitors: a mechanism for proteasome inhibitor-enhanced TRAIL-induced apoptosis.
Seol DW
Biochem Biophys Res Commun; 2011 Dec; 416(1-2):222-5. PubMed ID: 22120628
[TBL] [Abstract][Full Text] [Related]
20. PI3K/AKT pathway-mediated regulation of p27(Kip1) is associated with cell cycle arrest and apoptosis in cervical cancer.
Prasad SB; Yadav SS; Das M; Modi A; Kumari S; Pandey LK; Singh S; Pradhan S; Narayan G
Cell Oncol (Dordr); 2015 Jun; 38(3):215-25. PubMed ID: 25821107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
